Keywords
Hematopoietic malignancy of tibia - Histiocytic sarcoma - Neoplasm of histiocytic
origin - Primary histiocytic sarcoma of bone - Rare Neoplasm of bone - Reticulo sarcoma
Introduction
Histiocytic sarcoma is an extremely rare malignant neoplasm of the hematopoietic system
with poor prognosis, literature quotes its incidence of less than 1% of all hematolymphoid
neoplasms.[1] It is characterized by morphological and immunophenotypic features similar to those
of mature tissue histiocytes. There are expressions of histiocytic markers without
dendritic cell markers. Neoplastic proliferation associated with acute monocytic leukemia
should be excluded. Because a subset of cases occurs post mediastinal germ cell tumor,
particularly malignant teratoma and teratocarcinoma are known to differentiate along
hematopoietic lines. Thus, it is suggested that histiocytic sarcoma arises from pluripotent
germ cells.[2]
Clinically, it presents as a solitary mass that may be associated with fever and weight
loss. Other less common systemic features are lytic bony lesions, hepatosplenomegaly,
and pancytopenia. Three typical sites of involvement are lymph nodes, skin, and the
gastrointestinal system.[3] Immunohistochemically, these tumors are positive for one or more histiocytic markers
such as the cluster of differentiation (CD) 68 (KP1, PGM1), CD1 63, and lysozyme,
but negative for CD1 a, CD21, CD35, CD30, and T cell, B cell, and myeloid lineage
markers. S1 00 can be positive but is usually weak or focal. Ki67 is variable. With
the development of immunohistochemical (IHC) techniques, most previous reported cases
of HS are now generally recognized to be misdiagnosed examples of non-Hodgkin lymphomas,
predominantly diffuse large B cell lymphoma or anaplastic cell lymphoma.[4] Thus, histiocytic sarcoma is a frequently misdiagnosed and underreported entity.
This case report aims at reporting a rare incidence of histiocytic sarcoma at an atypical
site, i.e, tibial condyles.
Case Report
A 70-year-old female patient presented with pain and swelling in the left knee joint
since 2 months, with a tender hard swelling fixed to the bone. The X-ray of the left
knee joint showed a lytic lesion in the medial condyle of the left tibia. MRI showed
a well-defined, lytic, eccentric, expansile lesion in epimetaphysis of the proximal
tibia ([Fig 1a, b]). Biopsy was performed and histological features were suggestive of high-grade sarcoma
with possibilities of histiocytic sarcoma and epitheloid sarcoma. IHC was suggestive
of EMA S1 00 SMA focally positive, strongly positive for vimentin, CD 68 diffusely
positive, LCA, HLA DR lysozyme positive, suggestive of high-grade sarcoma consistent
with histiocytic sarcoma. Blood investigations showed red blood cell (RBC) counts
as 4.15 × 106/µL, white blood cell (WBC) count: 11,000/µL, and platelet count: 2.92 × 105/mm3. Bone marrow biopsy did not reveal any malignant infiltration. PET CT showed localized
increased metabolic uptake but no evidence of distant spread ([Fig. 2a, b]).
Fig. 1 (a) MRI coronal section through left knee joint showing lytic lesion in the medial condyle
of the tibia. (b) MRI sagittal section through the left knee joint. MRI, magnetic resonance imaging.
Fig. 2 (a) and (b) PET CT scan showing the FDG avid lesion in the medial condyle of the left tibia
and no distant metastasis. FDG: 18Fluro Deoxy Glucose PET CT, positron emission tomography-computed
tomography.
The case was discussed by the multidisciplinary tumor board. In view of the localized
disease, a plan for surgical treatment was made. Because excision would have led to
joint morbidity, curettage of bone marrow was done followed by local radiation therapy
(45 Gy in 25 fractions, 5 days a week over 5 weeks) with the IMRT: Intensity Modulated
Radiotherapy technique. Until the recent follow-up after 1.5 years of diagnosis, the
patient is disease-free.
Discussion
The term histiocytic sarcoma was used by Mathe in 1970 for an entity earlier known
by terms such as “reticulosarcoma”(Oberling), “recticulum cell lymphosarcoma” (Silhol),
and “retothelsarcom” (Roulet).[5] However, its description at that time was purely based on morphological similarity
to macrophages. Since then, attempts to establish its identity in histiocytic cell
lineages by immunohistochemical and cytochemical methods is going on. At present,
several markers are being used to establish the diagnosis of histiocytic malignancies
such as the cluster of differentiation (CD) 68 (KP1, PGM1), CD1 63, and lysozyme.
CD1 63, a hemoglobin scavenger receptor protein, is a novel marker used for identifying
histiocytic cells with a greater degree of specificity and is a promising marker in
the diagnosis of true histiocytic malignancies.[3]
[6]
[7] The World Health Organization (WHO) defines histiocytic sarcoma as a malignancy
with morphologic and immunophenotypic features that resemble those of mature tissue
histiocytes.[8]
The role of cytogenetics in diagnosis by studying TCR rearrangement or the absence
of the IgH gene has been studied and verified.[9] In 2001, the WHO stated that the absence of these genetic features is mandatory
for the establishment of the diagnosis of histiocytic sarcoma.[1]
This being a rare malignancy, a standard treatment regime is lacking. Treatment is
mostly on the lines of large cell lymphoma.[10] Studies have shown a relation of histiocytic sarcoma with B cell lymphoma lineage.
Further studies have also shown two subtypes M1 and M2 macrophages, whose role in
the diagnosis and treatment planning is yet to be established.[11] Biological closeness of histiocytic sarcoma with lymphoma indicates similar prognostic
values and treatment lines. For localized disease, surgical resection with or without
radiotherapy is indicated, while the systemic disease is treated with chemotherapy
regimens such as CHOP, CHOEP, and ICE. Evidence exists for other systemic treatment
options with targeted therapies such as alemtuzumab in histiocytic proliferative disorders
but further work is required before drawing any conclusions.[12]
Histiocytic sarcoma primarily affecting bone is a rare entity. Although secondary
bone involvement as a part of systemic disease is a well-known entity, the primary
bone involvement by histiocytic sarcoma is sparsely reported in the literature. Lage
et al reported disseminated primary bone disease that was confused with multiple myeloma.[13] They treated the patient with localized radiotherapy and systemic therapy. Bhalla
et al described a primary bone histiocytic sarcoma in the head and neck. The patient
was being treated with systemic therapy.[14] Our patient had a lesion in the tibial bone marrow. Because it was a completely
localized disease and was completely excised, systemic therapy was not advocated.
